Inovio Pharmaceuticals (INO) Q2 2024 earnings summary

Executive summary

• Lead program INO-3107 for recurrent respiratory papillomatosis (RRP) advanced, with BLA submission delayed to mid-2025 due to a device manufacturing issue; all non-device BLA elements expected by year-end.

• INO-3107 showed 81.3% of patients had reduced surgical interventions in Phase 1/2; regulatory progress in the U.S., U.K., and Europe, including UK ILAP Innovation Passport and EMA ATMP Certification.

• Pipeline progress includes INO-3112 (OPSCC) with Phase 3 plans in Europe and North America, and INO-4201 Ebola booster with strong Phase 1b results and Phase 2/3 protocol resubmission planned.

• Strengthened leadership with appointment of a new Chief Commercial Officer to enhance commercial readiness.

• Collaborations with major partners such as ApolloBio, Advaccine, AstraZeneca, and Gates Foundation.

Financial highlights

• Q2 2024 net loss was $32.2M ($1.19/share), improved from $35.5M ($1.61/share) in Q2 2023; revenue was $101,000 for Q2 2024.

• Cash, cash equivalents, and short-term investments totaled $110.4M as of June 30, 2024, with no debt after repaying convertible notes.

• Total operating expenses for Q2 2024 were $33.3M, down from $37.3M in Q2 2023; R&D expenses for Q2 2024 were $23.1M.

• General and administrative expenses fell to $10.2M for Q2 2024, mainly due to lower compensation and legal costs.

• Raised $33.2M in April 2024 through an equity and warrant offering.

Outlook and guidance

• Cash runway projected into Q3 2025, with current resources sufficient for at least 12 months; projections exclude future capital raises.

• BLA submission for INO-3107 now expected mid-2025 due to device manufacturing delays; all non-device BLA elements expected by year-end.

• INO-3112 Phase 3 trial start and INO-4201 Phase 2/3 protocol resubmission contingent on device issue resolution.

• Additional financing will be required to complete development and commercialization beyond INO-3107.